Superworth

Syndax Pharmaceuticals price to sales ratio SNDX

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026
4.7×
10-year median
66.7×
Against its 10-year history
0th
percentile: 0 is its lowest day, 100 its highest
10-year range
4.6× to 200×
Peer median
1.8×

Syndax Pharmaceuticals' price to sales ratio is 4.7× as of Oct 23, 2026.

That is below its ten-year median of 66.7×, lower than on 100% of days in the last ten years.

Over that time it ranged from 4.6× in Oct 2026 to 200× in Oct 2017.

The median for 10 large drugmakers of a similar size is 1.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.7×4.6×16.6×
202516.6×11.7×22.5×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
20229.6×5.7×69.8×
202180.0×58.8×82.1×
2020178×126×192×
2019160×52.7×183×
201843.1×38.7×198×
2017175×124×200×

Against its peers

Companies in Drug Manufacturers - General nearest Syndax Pharmaceuticals' size, closest first, today.

CompanyPrice to sales ratio
SNDXSyndax Pharmaceuticals4.7×
OMEROmerosn/m
AMPHAmphastar Pharmaceuticals1.5×
PCRXPacira BioSciences1.9×
ANABAnaptysbion/m
PAHCPhibro Animal Health1.0×
ANIPANI Pharmaceuticals1.7×
ABUSArbutus Biopharma4.6×
COLLCollegium Pharmaceutical0.9×
HRMYHarmony Biosciences2.2×
PBHPrestige Consumer Healthcare2.0×
Peer median1.8×

Where Syndax Pharmaceuticals ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Syndax Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.